
Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Targeted Search
Clinical Trials Search Results
Query: "AREA[SponsorSearch](Daiichi Pharmaceuticals)"
Count: 14
Selected: 0
NCT ID | Title |
---|
NCT00072228 | Soblidotin and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors | ||
NCT00005091 | DX-8951f in Treating Previously Untreated Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer | ||
NCT00002342 | A Study of Tecogalan Sodium | ||
NCT00002138 | A Phase I Trial of Tecogalan Sodium ( DS-4152 ) Administered as an Infusion Twice Weekly for 21 Days. | ||
NCT00002137 | A Phase I Trial of Tecogalan Sodium ( DS-4152 ) Administered as an Infusion Weekly x 4 | ||
NCT00002136 | A Phase I Trial of Tecogalan Sodium (DS-4152) Administered as an Infusion Every 21 Days | ||
NCT00325390 | Efficacy and Safety in Patients With Acute Coronary Syndrome Without ST-Segment Elevation | ||
NCT00221091 | Study to Evaluate Efficacy of Shunt Operation for Idiopathic Normal Pressure Hydrocephalus | ||
NCT00284258 | Phase II/III Trial of CPT-11/5-FU/l-LV Versus CPT-11/TS-1 as Second Line Chemotherapy of Unresectable Colorectal Cancer | ||
NCT01813253 | Phase 3 Study of Nimotuzumab and Irinotecan as Second Line With Advanced or Recurrect Gastric and Gastroesophageal Junction Cancer | ||
NCT00872586 | Evaluation of the Additional Efficacy, and Safety of Olmesartan Medoxomil 20mg / Hydrochlorothiazide 12.5mg in the Treatment of Chinese Patients With Mild to Moderate Essential Hypertension | ||
NCT00856271 | Olmesartan Medoxomil Versus Losartan Potassium in Patients With Mild to Moderate Essential Hypertension | ||
NCT02647307 | Study of the Effects of Ethnicity on the Pharmacokinetics, Pharmacodynamics and Safety of DS-1040b | ||
NCT01582217 | Patients Undergoing Percutaneous Coronary Intervention (PCI) Through Optimal Platelet Inhibition |